ClinicalTrials.gg
Sign In
CompletedNCT03933033Updated May 1, 2019

Erbium-YAG Laser Versus Platelet Rich Plasma in the Treatment of Atrophic Acne Scars

An interventional study of Fractional Erbium Yağ Laser and Platelet Rich Plasma in Acne Vulgaris and Scars, sponsored by Aswan University Hospital. Completed at 1 site in Egypt. Open to participants aged 18 Years to 38 Years. Per ClinicalTrials.gov, last updated 2019-05-01.

Sponsored by Aswan University Hospital · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Jun 2017, registered Apr 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 38 Years
Sex
All
01

Study summary

This study aim to assess the efficacy of Er-YAG laser 2940nm and PRP as a single line of treatment in comparison with combined treatment in atrophic post acne scars.

02

Conditions studied

  • Acne Vulgaris
  • Scars

Keywords

  • Acne scars
  • Erbium-YAG laser
  • platelet-rich plasma
03

In context

Acne Vulgaris

750 studies on the registry are indexed under Acne Vulgaris; 89 are open to participants now.

This study's enrollment of 75 is close to the median of 69 across 647 interventional studies indexed under Acne Vulgaris.

Browse Acne Vulgaris studies →

Lead sponsor

Aswan University Hospital is the lead sponsor of 97 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 38 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with atrophic post acne scars classified on the basis of Goodman and Baron's Qualitative classification, no active acne lesions and patients with atrophic scars only

Exclusion criteria

Exclusion Criteria:

  • patients with positive history of keloidal tendency, positive history of bleeding tendency, platelet disorder, patients with any acute infection on face like, herpes, folliculitis, patients with HIV, HBsAg, patients with a history of autoimmune diseases or patients on immunosuppressive drugs.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
75 participants (actual)

Study arms

  • Active comparator
    Group A

    treated with platelet rich plasma

    Procedure: Platelet Rich Plasma

  • Active comparator
    Group B

    treated with Erbium Yag Laser

    Device: Fractional Erbium Yağ Laser

  • Active comparator
    Group C

    treated with both line of treatments

    Device: Fractional Erbium Yağ Laser · Procedure: Platelet Rich Plasma

Interventions

  • DeviceFractional Erbium Yağ Laser

    Multiple sessions of Fractional Erbium Yağ Laser

  • ProcedurePlatelet Rich Plasma

    Multiple injections of Platelet Rich Plasma

06

What researchers measure

Primary outcomes

  1. Change in grade of acne scares according toQualitative scarring grading system of Goodman and Baron

    Grade of acne scares improvement after treatment

    Time frame: 6 months

  2. Change in clinical appearance of acne scare accordinga four-point scale for assessment of clinical improvement of skin smoothness

    improvement of acne scares as evaluated by sequential photos

    Time frame: 6 month

  3. Change in patient satisfaction usinga four-point scale; Grade 4 highly satisfied, Grade 3 satisfied, Grade 2 neutral and Grade 1 dissatisfied

    increase in patient satisfaction after treatment

    Time frame: 6 month

07

Study locations

1 site
  • Aswan University Hospital
    Aswān, 81528, Egypt
08

References and documents

Publications

  • El-Taieb MA, Ibrahim HM, Hegazy EM, Ibrahim AK, Gamal AM, Nada EA. Fractional Erbium-YAG Laser and Platelet-Rich Plasma as Single or Combined Treatment for Atrophic Acne Scars: A Randomized Clinical Trial. Dermatol Ther (Heidelb). 2019 Dec;9(4):707-717. doi: 10.1007/s13555-019-00318-1. Epub 2019 Aug 16. PubMed 31420849 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in Aug 2018, 14 months.

Of 61 non-industry interventional studies with no phase under Acne Vulgaris, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 17. This study's 14 months is above that.

Counting every sponsor, half of 116 studies reached it within 9 months; a quarter within 4 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2019
First posted
May 1, 2019
StartActual
Jun 1, 2017
Primary completionActual
Aug 31, 2018
CompletionActual
Feb 28, 2019
Last update
May 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03933033
Lead sponsor
Aswan University Hospital
Collaborators
South Valley University
Responsible party
Moustafa A. El Taieb (Ass. Prof. of Dermatology, Venereology and Andrology, Aswan University Hospital) — Principal investigator
First posted
May 1, 2019
Start date
Jun 1, 2017
Primary completion
Aug 31, 2018
Completion
Feb 28, 2019
Last update
May 1, 2019

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Acne Vulgaris →

Other studies from this sponsor

Aswan University Hospital

Start the discussion